Caldera (Caldera Pharmaceuticals) Deal History & Licensing Activity
Caldera (Caldera Pharmaceuticals) is a life sciences. Over the past three years, Caldera (Caldera Pharmaceuticals) has been involved in 1 licensing and acquisition transaction, with a primary focus on Bispecific Antibodies (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Bispecific Antibodies
Focus Area
Gastroenterology
Caldera (Caldera Pharmaceuticals) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Caldera (Caldera Pharmaceuticals) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| CLD-423 (bispecific IL-23p19/TL1A antibody) | Qyuns Therapeutics | Bispecific Antibodies | Phase 1 | license | Apr 2026 |
Caldera (Caldera Pharmaceuticals) Pipeline Focus
Therapeutic areas and modalities where Caldera (Caldera Pharmaceuticals) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Caldera (Caldera Pharmaceuticals)'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Gastroenterology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Caldera (Caldera Pharmaceuticals) Licensing & Deal Activity
Caldera (Caldera Pharmaceuticals) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Caldera (Caldera Pharmaceuticals) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Caldera (Caldera Pharmaceuticals) include Gastroenterology (2 deals and trials). In terms of modality, Caldera (Caldera Pharmaceuticals) has shown particular interest in bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Caldera (Caldera Pharmaceuticals) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Caldera (Caldera Pharmaceuticals)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.